Logo image of EMEIS.PA

EMEIS SA (EMEIS.PA) Stock Fundamental Analysis

EPA:EMEIS - Euronext Paris - Matif - FR001400NLM4 - Common Stock - Currency: EUR

12.234  +0.22 (+1.8%)

Fundamental Rating

4

Overall EMEIS gets a fundamental rating of 4 out of 10. We evaluated EMEIS against 23 industry peers in the Health Care Providers & Services industry. There are concerns on the financial health of EMEIS while its profitability can be described as average. EMEIS is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

In the past year EMEIS was profitable.
EMEIS had a positive operating cash flow in the past year.
Of the past 5 years EMEIS 4 years were profitable.
In the past 5 years EMEIS always reported a positive cash flow from operatings.
EMEIS.PA Yearly Net Income VS EBIT VS OCF VS FCFEMEIS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1B -1B -2B -3B -4B

1.2 Ratios

EMEIS has a Return On Assets of 10.61%. This is amongst the best in the industry. EMEIS outperforms 100.00% of its industry peers.
EMEIS has a Return On Equity of 76.36%. This is amongst the best in the industry. EMEIS outperforms 100.00% of its industry peers.
Industry RankSector Rank
ROA 10.61%
ROE 76.36%
ROIC N/A
ROA(3y)-5.89%
ROA(5y)-3.02%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EMEIS.PA Yearly ROA, ROE, ROICEMEIS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 100 150 200 250

1.3 Margins

EMEIS has a Profit Margin of 27.04%. This is amongst the best in the industry. EMEIS outperforms 100.00% of its industry peers.
In the last couple of years the Profit Margin of EMEIS has grown nicely.
The Operating Margin and Gross Margin are not available for EMEIS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 27.04%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y85.55%
PM growth 5Y32.24%
GM growth 3YN/A
GM growth 5YN/A
EMEIS.PA Yearly Profit, Operating, Gross MarginsEMEIS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 -40 -60 -80

More info and screens

2

2. Health

2.1 Basic Checks

EMEIS does not have a ROIC to compare to the WACC, probably because it is not profitable.
EMEIS has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, EMEIS has less shares outstanding
The debt/assets ratio for EMEIS has been reduced compared to a year ago.
EMEIS.PA Yearly Shares OutstandingEMEIS.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B
EMEIS.PA Yearly Total Debt VS Total AssetsEMEIS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5B 10B 15B

2.2 Solvency

Based on the Altman-Z score of 0.57, we must say that EMEIS is in the distress zone and has some risk of bankruptcy.
EMEIS has a worse Altman-Z score (0.57) than 69.23% of its industry peers.
A Debt/Equity ratio of 4.15 is on the high side and indicates that EMEIS has dependencies on debt financing.
EMEIS's Debt to Equity ratio of 4.15 is on the low side compared to the rest of the industry. EMEIS is outperformed by 84.62% of its industry peers.
Industry RankSector Rank
Debt/Equity 4.15
Debt/FCF N/A
Altman-Z 0.57
ROIC/WACCN/A
WACC4.86%
EMEIS.PA Yearly LT Debt VS Equity VS FCFEMEIS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2B 4B 6B 8B

2.3 Liquidity

EMEIS has a Current Ratio of 0.67. This is a bad value and indicates that EMEIS is not financially healthy enough and could expect problems in meeting its short term obligations.
EMEIS has a worse Current ratio (0.67) than 65.38% of its industry peers.
EMEIS has a Quick Ratio of 0.67. This is a bad value and indicates that EMEIS is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.67, EMEIS perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.67
Quick Ratio 0.67
EMEIS.PA Yearly Current Assets VS Current LiabilitesEMEIS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2B 4B 6B 8B

More info and screens

7

3. Growth

3.1 Past

EMEIS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 220.29%, which is quite impressive.
The Earnings Per Share has been growing by 116.08% on average over the past years. This is a very strong growth
Looking at the last year, EMEIS shows a quite strong growth in Revenue. The Revenue has grown by 10.24% in the last year.
The Revenue has been growing by 8.73% on average over the past years. This is quite good.
EPS 1Y (TTM)220.29%
EPS 3Y301.6%
EPS 5Y116.08%
EPS Q2Q%-360.92%
Revenue 1Y (TTM)10.24%
Revenue growth 3Y9.84%
Revenue growth 5Y8.73%
Sales Q2Q%9.16%

3.2 Future

Based on estimates for the next years, EMEIS will show a very strong growth in Earnings Per Share. The EPS will grow by 25.87% on average per year.
EMEIS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.79% yearly.
EPS Next Y98.31%
EPS Next 2Y41.32%
EPS Next 3Y25.87%
EPS Next 5YN/A
Revenue Next Year8.21%
Revenue Next 2Y8.86%
Revenue Next 3Y7.79%
Revenue Next 5YN/A

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
EMEIS.PA Yearly Revenue VS EstimatesEMEIS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2B 4B 6B
EMEIS.PA Yearly EPS VS EstimatesEMEIS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 100 -100 200

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 2.49, which indicates a rather cheap valuation of EMEIS.
Based on the Price/Earnings ratio, EMEIS is valued cheaply inside the industry as 96.15% of the companies are valued more expensively.
EMEIS's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 29.35.
The Forward Price/Earnings Ratio is negative for EMEIS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 2.49
Fwd PE N/A
EMEIS.PA Price Earnings VS Forward Price EarningsEMEIS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EMEIS.PA Per share dataEMEIS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

EMEIS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as EMEIS's earnings are expected to grow with 25.87% in the coming years.
PEG (NY)0.03
PEG (5Y)0.02
EPS Next 2Y41.32%
EPS Next 3Y25.87%

More info and screens

0

5. Dividend

5.1 Amount

EMEIS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EMEIS SA

EPA:EMEIS (3/7/2025, 7:00:00 PM)

12.234

+0.22 (+1.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)01-16 2025-01-16/amc
Earnings (Next)05-12 2025-05-12
Inst Owners55.18%
Inst Owner ChangeN/A
Ins Owners0.81%
Ins Owner ChangeN/A
Market Cap1.98B
Analysts80
Price Target10.2 (-16.63%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-12.28%
PT rev (3m)-12.28%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-14.02%
EPS NY rev (3m)-203.79%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.38%
Revenue NY rev (3m)3.7%
Valuation
Industry RankSector Rank
PE 2.49
Fwd PE N/A
P/S 0.36
P/FCF N/A
P/OCF 5.84
P/B 1.03
P/tB N/A
EV/EBITDA N/A
EPS(TTM)4.92
EY40.22%
EPS(NY)-0.38
Fwd EYN/A
FCF(TTM)-1.28
FCFYN/A
OCF(TTM)2.1
OCFY17.14%
SpS33.64
BVpS11.91
TBVpS-5.82
PEG (NY)0.03
PEG (5Y)0.02
Profitability
Industry RankSector Rank
ROA 10.61%
ROE 76.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 27.04%
GM N/A
FCFM N/A
ROA(3y)-5.89%
ROA(5y)-3.02%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y85.55%
PM growth 5Y32.24%
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 4.15
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 10.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.67
Quick Ratio 0.67
Altman-Z 0.57
F-Score6
WACC4.86%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)13.91%
Cap/Sales(5y)16.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)220.29%
EPS 3Y301.6%
EPS 5Y116.08%
EPS Q2Q%-360.92%
EPS Next Y98.31%
EPS Next 2Y41.32%
EPS Next 3Y25.87%
EPS Next 5YN/A
Revenue 1Y (TTM)10.24%
Revenue growth 3Y9.84%
Revenue growth 5Y8.73%
Sales Q2Q%9.16%
Revenue Next Year8.21%
Revenue Next 2Y8.86%
Revenue Next 3Y7.79%
Revenue Next 5YN/A
EBIT growth 1Y80.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year124.45%
EBIT Next 3Y31.64%
EBIT Next 5YN/A
FCF growth 1Y64.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-52.42%
OCF growth 3Y-22.21%
OCF growth 5Y-2.48%